© 2020 MJH Life Sciences and OncLive. All rights reserved.
Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.
Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.
During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.
By: Constantine S. Tam, MD, MBBS
Constantine S. Tam, MD, MBBS, discusses the 3 FDA approved BTK inhibitors in hematologic malignancies: ibrutinib, acalabrutinib, and zanubrutinib.
Constantine S. Tam, MD, MBBS, discusses the FDA approval of zanubrutinib in mantle cell lymphoma.
By: Brad Kahl, MD
Brad Kahl, MD, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia.
Constantine S. Tam, MD, MBBS, discusses a comparison of BTK inhibitors in mantle cell lymphoma.
Brad Kahl, MD, discusses choosing between BTK inhibitors ibrutinib and acalabrutinib for frontline treatment of chronic lymphocytic leukemia.